A. U. Hamadianova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. U. Hamadianova has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- A. R. Ibragimova
Samara State Medical University
2 shared publications - Indira V. Sakhautdinova
Bashkir State Medical University, Ministry of Health of the Russian Federation
2 shared publications - Kirill O. Kuznetsov
Ufa University of Science and Technology
2 shared publications - Regina B. Balter
Samara State Medical University
2 shared publications - Tatiana V. Ivanova
Samara State Medical University
2 shared publications - A. R. Semenova
Russian Scientific Center of Roentgenoradiology
1 shared publication
Latest Publications
- 24 June 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 24 (3)
Relationship between pregnancy and the risk of malignant neoplasms of the female reproductive system
Ovarian cancer (OC) is the 8th most common cancer in women, affecting about 300.000 patients worldwide and causing 207.000 deaths annually. OC serves as the leading cause of death among gynecologic cancers. Endometrial cancer (EC) is the 6th most common cancer amoung women worldwide with more than 410.000 new cases confirmed in 2020. Since the late 1990s, epidemiologic studies have revealed an inverse negative association between multiple pregnancies and the incidence of OC and EC. In addition, a later onset of the disease was found in multiparous women, as well as an overall decrease in the incidence of OC. Objective. To review the available literature evaluating the association between pregnancy and the incidence of OC and EC, and to discuss non-hormonal mechanisms that may contribute to protection against the development of OC and EC in pregnancy. Current evidence suggests that not only reproductive endocrine factors but also non-reproductive factors, including the maternal immune response to the fetus, may be regulated by placental extracellular vesicles. Further studies are needed to unravel the protective mechanisms of pregnancy, which being best understood, may provide a novel approach to future cancer therapy.
- 24 June 2024
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 24 (3)
Relationship between pregnancy and the risk of malignant neoplasms of the female reproductive system
Ovarian cancer (OC) is the 8th most common cancer in women, affecting about 300.000 patients worldwide and causing 207.000 deaths annually. OC serves as the leading cause of death among gynecologic cancers. Endometrial cancer (EC) is the 6th most common cancer amoung women worldwide with more than 410.000 new cases confirmed in 2020. Since the late 1990s, epidemiologic studies have revealed an inverse negative association between multiple pregnancies and the incidence of OC and EC. In addition, a later onset of the disease was found in multiparous women, as well as an overall decrease in the incidence of OC. Objective. To review the available literature evaluating the association between pregnancy and the incidence of OC and EC, and to discuss non-hormonal mechanisms that may contribute to protection against the development of OC and EC in pregnancy. Current evidence suggests that not only reproductive endocrine factors but also non-reproductive factors, including the maternal immune response to the fetus, may be regulated by placental extracellular vesicles. Further studies are needed to unravel the protective mechanisms of pregnancy, which being best understood, may provide a novel approach to future cancer therapy.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 23 (5)
Perinatal outcomes and immunological changes in pregnant women with new COVID-19 coronavirus infection
A review of scientific works published over the last 3 years concerning the issue of immunological changes and related perinatal outcomes in pregnant women with COVID-19 was carried out. It was found that pregnant women are more likely to have a severe course of COVID-19. This is largely due to immune changes in the pregnant woman’s body, as well as to the pathophysiology of COVID-19. This article discusses the main immunological changes, such as reduced levels of natural killer cells (NK cells), type 1 T-helper cells (Th1), plasmacytoid dendritic cells (pDCs), decreased phagocytic index of neutrophilic granulocytes and monocytes, as well as immunomodulatory properties of progesterone, the content of which is increased in pregnancy. Factors that may exacerbate the course of the disease due to hyperinflammatory states include an increase in the complement system, which is associated with more severe lung injury, and an increase in TLR-1 and TLR-7 toll-like receptors that bind to the virus, leading to increased production of pro-inflammatory cytokines such as IL-6 and TNF-α, which are elevated in the normal physiology of pregnancy. This leads to a higher incidence of pre-eclampsia, eclampsia, preterm labor and other adverse outcomes in pregnant women with COVID-19.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 23 (5)
Perinatal outcomes and immunological changes in pregnant women with new COVID-19 coronavirus infection
A review of scientific works published over the last 3 years concerning the issue of immunological changes and related perinatal outcomes in pregnant women with COVID-19 was carried out. It was found that pregnant women are more likely to have a severe course of COVID-19. This is largely due to immune changes in the pregnant woman’s body, as well as to the pathophysiology of COVID-19. This article discusses the main immunological changes, such as reduced levels of natural killer cells (NK cells), type 1 T-helper cells (Th1), plasmacytoid dendritic cells (pDCs), decreased phagocytic index of neutrophilic granulocytes and monocytes, as well as immunomodulatory properties of progesterone, the content of which is increased in pregnancy. Factors that may exacerbate the course of the disease due to hyperinflammatory states include an increase in the complement system, which is associated with more severe lung injury, and an increase in TLR-1 and TLR-7 toll-like receptors that bind to the virus, leading to increased production of pro-inflammatory cytokines such as IL-6 and TNF-α, which are elevated in the normal physiology of pregnancy. This leads to a higher incidence of pre-eclampsia, eclampsia, preterm labor and other adverse outcomes in pregnant women with COVID-19.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 23 (4)
The role of microRNAs in normal condition and in endometrial pathology
The endometrium is a tissue of the human body that undergoes monthly structural cyclic changes. MicroRNAs are non-coding small RNAs responsible for the post-transcriptional regulation of gene expression. The action of each microRNA is tissue specific and cannot extend to other organs. MicroRNA expression patterns in normal and pathologically altered endometrium are now widely discussed. MicroRNA expression profiles in the human endometrium vary according to the phase of the menstrual cycle and are regulated by sex hormones. At the same time, microRNAs can influence the action of sex hormones, so that modification of the microRNA expression profile in a pathological endometrium can either be the cause or the result of pathology. Deregulated microRNAs detected in patients with repeated implantation failures are often involved in the processes of adhesion, proliferation and angiogenesis. In endometriosis, the microRNAs detected are often associated with cell proliferation, apoptosis and adhesion. Finally, microRNAs involved in epithelial-mesenchymal transition are often detected in endometrial cancer. The development of technologies that allow global analysis of known microRNAs in the human endometrium may allow a better understanding of their action and lead to the development of new diagnostic and therapeutic modalities.
- 23 April 2023
- Published by Media Sphere Publishing Group in Russian Bulletin of Obstetrician-Gynecologist
- Vol. 23 (4)
The role of microRNAs in normal condition and in endometrial pathology
The endometrium is a tissue of the human body that undergoes monthly structural cyclic changes. MicroRNAs are non-coding small RNAs responsible for the post-transcriptional regulation of gene expression. The action of each microRNA is tissue specific and cannot extend to other organs. MicroRNA expression patterns in normal and pathologically altered endometrium are now widely discussed. MicroRNA expression profiles in the human endometrium vary according to the phase of the menstrual cycle and are regulated by sex hormones. At the same time, microRNAs can influence the action of sex hormones, so that modification of the microRNA expression profile in a pathological endometrium can either be the cause or the result of pathology. Deregulated microRNAs detected in patients with repeated implantation failures are often involved in the processes of adhesion, proliferation and angiogenesis. In endometriosis, the microRNAs detected are often associated with cell proliferation, apoptosis and adhesion. Finally, microRNAs involved in epithelial-mesenchymal transition are often detected in endometrial cancer. The development of technologies that allow global analysis of known microRNAs in the human endometrium may allow a better understanding of their action and lead to the development of new diagnostic and therapeutic modalities.
- Open Access
- 4 September 2022
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 68 (6) , 146-156
Androgens and Parkinson’s disease: the role in humans and in experiment
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is evidence that PD has a wider prevalence among men, which indicates the existing role of sex hormones in the pathogenesis of the disease. The article presents an overview of studies devoted to the study of sex differences in the incidence and symptoms of PD. Drug therapy with androgens, androgen precursors, antiandrogens and drugs that modify androgen metabolism is available for the treatment of various endocrine conditions, having translational significance for PD, but none of these drugs has yet shown sufficient effectiveness. Although PD has now been proven to be more common in men than in women, androgens do not always have any effect on the symptoms or progression of the disease. 5α-reductase inhibitors have shown neuroprotective and anti-dyskinetic activity and need further investigation. Despite the fact that the neuroprotective effect of dutasteride was observed only before damage to DA neurons, the absence of a negative effect makes it an attractive drug for use in patients with PD due to its anti-dyskinetic properties.
- 4 September 2022
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 68 (6) , 146-156
Open AccessAndrogens and Parkinson’s disease: the role in humans and in experiment
Parkinson’s disease (PD) is the second most common neurodegenerative disease after Alzheimer’s disease. There is evidence that PD has a wider prevalence among men, which indicates the existing role of sex hormones in the pathogenesis of the disease. The article presents an overview of studies devoted to the study of sex differences in the incidence and symptoms of PD. Drug therapy with androgens, androgen precursors, antiandrogens and drugs that modify androgen metabolism is available for the treatment of various endocrine conditions, having translational significance for PD, but none of these drugs has yet shown sufficient effectiveness. Although PD has now been proven to be more common in men than in women, androgens do not always have any effect on the symptoms or progression of the disease. 5α-reductase inhibitors have shown neuroprotective and anti-dyskinetic activity and need further investigation. Despite the fact that the neuroprotective effect of dutasteride was observed only before damage to DA neurons, the absence of a negative effect makes it an attractive drug for use in patients with PD due to its anti-dyskinetic properties.
- Open Access
- 16 October 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 216-222
Human papillomavirus-associated cervical intraepithelial neoplasia in the presence of iodine deficiency
Introduction. Cervical cancer holds one of the top positions in the oncological diseases ranking among the female population in the presence of iodine deficiency in the territory of the Republic of Bashkortostan. It's commonly believed that it is caused by the development of cervical intraepithelial neoplasia (CIN) associated with highly oncogenic strains of the human papillomavirus (HPV). The article pays special attention to the risk factors for the development of precancerous and cancerous diseases of the cervix and their timely treatment.The aim of the study was to improve the diagnosis and therapy of HPV-associated CIN in the presence of iodine deficiency in the Republic of Bashkortostan.Materials and methods. 256 women aged between 21 and 45 years with identified HPV-associated CIN I were enrolled in our study. The first stage of treatment known as preoperative was carried out in the outpatient setting. At stage 2, the patients were offered a radio-wave surgery treatment of the cervix.Results and discussion. The video colposcope analysis showed that the average time of epithelialization of the cervix after exposure to the destruction depended on the age and duration of the disease. For instance, complete epithelialization of the cervix in the group of patients aged between 21 to 38 years was reported in 72% of cases by Day 40, and in 62% of cases in the group of 39-45 years old on Day 40. The complete elimination of the virus was observed in 236 patients out of 256 cases (92%) 70 days after the end of therapy.Сonclusion. The study proves the effectiveness of the combination treatment of patients with HPV-associated CIN.
- 16 October 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 216-222
Open AccessHuman papillomavirus-associated cervical intraepithelial neoplasia in the presence of iodine deficiency
Introduction. Cervical cancer holds one of the top positions in the oncological diseases ranking among the female population in the presence of iodine deficiency in the territory of the Republic of Bashkortostan. It's commonly believed that it is caused by the development of cervical intraepithelial neoplasia (CIN) associated with highly oncogenic strains of the human papillomavirus (HPV). The article pays special attention to the risk factors for the development of precancerous and cancerous diseases of the cervix and their timely treatment.The aim of the study was to improve the diagnosis and therapy of HPV-associated CIN in the presence of iodine deficiency in the Republic of Bashkortostan.Materials and methods. 256 women aged between 21 and 45 years with identified HPV-associated CIN I were enrolled in our study. The first stage of treatment known as preoperative was carried out in the outpatient setting. At stage 2, the patients were offered a radio-wave surgery treatment of the cervix.Results and discussion. The video colposcope analysis showed that the average time of epithelialization of the cervix after exposure to the destruction depended on the age and duration of the disease. For instance, complete epithelialization of the cervix in the group of patients aged between 21 to 38 years was reported in 72% of cases by Day 40, and in 62% of cases in the group of 39-45 years old on Day 40. The complete elimination of the virus was observed in 236 patients out of 256 cases (92%) 70 days after the end of therapy.Сonclusion. The study proves the effectiveness of the combination treatment of patients with HPV-associated CIN.
- Open Access
- 16 October 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 170-175
Patterns of clinical presentation of climacteric syndrome and total body composition in women with menopausal metabolic syndrome
Introduction. Modern gynecological endocrinology widely discusses various disorders accompanying the onset of menopause. Metabolic disorders are one of the leading risk factors for the development of ischemic heart disease and vascular dystonia in menopausal women. That is why the drugs prescribed as part of menopausal hormone therapy are contraindicated for patients with severe metabolic disorders and predisposition to thrombosis. Women with a normal body mass index may develop the menopausal metabolic syndrome, since its presentations largely depend on the total body composition and the specific gravity of visceral adipose tissue.Aim. To assess the patterns of clinical presentation of menopause in women with metabolic menopausal syndrome.Materials and methods. In the furtherance of that aim, we examined 184 women who were in menopause 1 to 5 years at the age of 52 to 57 years (average age 54.2 ± 0.5 years). Of these, 87 were diagnosed with metabolic syndrome – they were included in the main group. The comparison group included 97 menopausal women without metabolic disorders.Results and discussion. We assessed the severity of clinical presentations and the total body composition of the patients in the selected groups. It has been established that the body mass index cannot serve as a criterion for evaluation of metabolic processes, despite the sufficient simplicity of its computation.Conclusions. The authentic view of the risks of metabolic disorders in menopausal women requires the study of total body composition.
- 16 October 2021
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 13,p. 170-175
Open AccessPatterns of clinical presentation of climacteric syndrome and total body composition in women with menopausal metabolic syndrome
Introduction. Modern gynecological endocrinology widely discusses various disorders accompanying the onset of menopause. Metabolic disorders are one of the leading risk factors for the development of ischemic heart disease and vascular dystonia in menopausal women. That is why the drugs prescribed as part of menopausal hormone therapy are contraindicated for patients with severe metabolic disorders and predisposition to thrombosis. Women with a normal body mass index may develop the menopausal metabolic syndrome, since its presentations largely depend on the total body composition and the specific gravity of visceral adipose tissue.Aim. To assess the patterns of clinical presentation of menopause in women with metabolic menopausal syndrome.Materials and methods. In the furtherance of that aim, we examined 184 women who were in menopause 1 to 5 years at the age of 52 to 57 years (average age 54.2 ± 0.5 years). Of these, 87 were diagnosed with metabolic syndrome – they were included in the main group. The comparison group included 97 menopausal women without metabolic disorders.Results and discussion. We assessed the severity of clinical presentations and the total body composition of the patients in the selected groups. It has been established that the body mass index cannot serve as a criterion for evaluation of metabolic processes, despite the sufficient simplicity of its computation.Conclusions. The authentic view of the risks of metabolic disorders in menopausal women requires the study of total body composition.